Lv2
120 积分 2025-07-26 加入
Exploration of Multiple Non‐Invasive Tests for Assessing Response to Treatment in a Semaglutide Phase 2b Trial in Patients with MASH
1个月前
已完结
Multi-omics analysis of hepatic outcomes in T2DM-MAFLD patients treated with semaglutide: a single-centre, longitudinal, data-driven study
1个月前
已完结
Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial
1个月前
已完结
FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption
2个月前
已完结
Retatrutide and lipid and metabolite profiles in participants with obesity with or without type 2 diabetes
3个月前
已关闭
GLP-1 Receptor Agonist Treatment Improves Fasting and Postprandial Lipidomic Profiles Independently of Diabetes and Weight Loss
3个月前
已完结
Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m2 but without diabetes: A phase 2 randomized controlled trial
5个月前
已完结
Beyond fat: Does semaglutide affect lean mass?
7个月前
已完结
Glucagon‐like peptide‐1 receptor agonist treatment associated weight fluctuation and influencing factors in patients with overweight or obesity
7个月前
已完结
Semaglutide for the treatment of cognitive dysfunction in major depressive disorder: A randomized clinical trial
7个月前
已完结
皖公网安备34019202002308
